A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Journal titleThe New England journal of medicine
Publication Begin page921
Publication End page5
MetadataShow full item record
AbstractCurrently, there is no single-dose therapy that is effective in the treatment of urethral or endocervical infections with Chlamydia trachomatis. Azithromycin is a new azalide antibiotic that has substantial activity against C. trachomatis, is concentrated intracellularly, and has a long half-life in serum and tissue.
We conducted a trial in which 299 female patients and 158 male patients with uncomplicated genital infection and a positive C. trachomatis antigen test were randomly assigned to receive either azithromycin (1 g once orally) or doxycycline (100 mg orally twice daily for seven days). Only patients subsequently determined to have a culture positive for C. trachomatis at base line were included in the evaluation of efficacy.
Among the patients who could be evaluated, 5 of the 141 patients (4 percent) treated with azithromycin did not respond to treatment, as compared with 3 of the 125 patients (2 percent) treated with doxycycline (difference between groups, 2 percent; 95 percent confidence interval, 0 to 6 percent). Of the patients evaluated 21 to 35 days after treatment, none of 112 treated with azithromycin and 1 of 102 treated with doxycycline had a positive culture. The rates of bacteriologic cure were similar for the 98 female patients (97 percent) and the 43 male patients (95 percent) treated with azithromycin. Seventeen percent of the patients who received azithromycin and 20 percent of those treated with doxycycline had mild-to-moderate drug-related side effects, mainly gastrointestinal symptoms.
A single 1-g dose of azithromycin is as effective for the treatment of uncomplicated genital chlamydial infections as a standard seven-day course of doxycycline.
CitationMartin DH, Mroczkowski TF, Dalu ZA, McCarty J, Jones RB, Hopkins SJ, Johnson RB. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N Engl J Med. 1992 Sep 24;327(13):921-5. doi: 10.1056/NEJM199209243271304. PMID: 1325036.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
- The demographic and behavioural profile of women with cervicitis infected with Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum and the comparison of two medical regimens.
- Authors: Guven MA, Gunyeli I, Dogan M, Ciragil P, Bakaris S, Gul M
- Issue date: 2005 Sep
- Efficacy and safety of ofloxacin in the treatment of nongonococcal sexually transmitted disease.
- Authors: Batteiger BE, Jones RB, White A
- Issue date: 1989 Dec 29
- Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises.
- Authors: Thorpe EM Jr, Stamm WE, Hook EW 3rd, Gall SA, Jones RB, Henry K, Whitworth G, Johnson RB
- Issue date: 1996 Apr
- Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study.
- Authors: Stamm WE, Hicks CB, Martin DH, Leone P, Hook EW 3rd, Cooper RH, Cohen MS, Batteiger BE, Workowski K, McCormack WM
- Issue date: 1995 Aug 16